Drugs / alpha1H
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03560479 | May 2018 → Dec 2021 | non-invasive bladder urothelial carcinoma | Hamlet Pharma AB | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alpha1H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03560479 ↗ |
| Modality | Peptide | “The investigational product alpha1H is a synthetic peptide” NCT03560479 ↗ |
| Route | Other | “Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)” NCT03560479 ↗ |